1. Accueil >
  2. Novo Nordisk: FDA posts briefing materials prior to Advisory Committee meeting for semaglutide >
Nasdaq

Novo Nordisk: FDA posts briefing materials prior to Advisory Committee meeting for semaglutide

16-10-2017


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via GlobeNewswire

HUG#2142021